May 2026 Research Update

Across this month's papers, the main pattern was early, mostly small studies looking at targeted immune medicines for dermatomyositis, often in people whose disease was difficult to control. Several reports described improvement in skin symptoms, itch, or muscle strength, but the evidence is still limited because most data were from retrospective series or a few individual patients. One phase 3 brepocitinib trial was mentioned, but no outcomes were provided in the available summary, so its benefits and risks cannot be interpreted here. [1] [2] [3] [4] [5]

In a 5-person retrospective case series focused on severe itch, all patients reported less itching after starting nemolizumab, and skin disease activity scores also improved. Some patients reported itch relief very quickly, and the medicine was described as well tolerated with no serious side effects in this small group. [2]

Two people with refractory dermatomyositis treated with anifrolumab had almost complete improvement of skin symptoms, and their type I interferon blood signature decreased during treatment. This supports the idea that type I interferon pathways may matter in dermatomyositis, but it is based on only two patients. [3]

A 9-patient retrospective pediatric study (dermatomyositis or juvenile dermatomyositis) reported sustained improvement in muscle strength measures after tumor necrosis factor (TNF) inhibitor treatment (infliximab or adalimumab) and a large reduction in daily steroid dose by 12 months. In a small subgroup with anti-NXP2 antibodies, calcinosis shrank on X-rays in 2 of 3 patients after 12 to 20 months, while one patient with pre-existing interstitial lung abnormalities worsened and stopped treatment. [4]

A single-center Polish cohort describing treatment patterns across idiopathic inflammatory myopathies reported that standard approaches often combined steroids with other immune suppressing medicines, and that some patients also received newer options such as rituximab, Janus kinase (JAK) inhibitors, anifrolumab, sirolimus, or nintedanib for lung disease. The report described generally acceptable disease control and safety in this specialized clinic population, but results were descriptive rather than a head-to-head comparison. [5]

For patients and caregivers, these papers mainly add background about what doctors are trying in harder-to-treat dermatomyositis, especially for skin symptoms and severe itch, and in some children for muscle weakness and calcinosis. The clearest limits are that most reports were small and retrospective (or just a couple of patients), so it is still uncertain how well these treatments work across different dermatomyositis subtypes and what the full safety picture looks like. The mention of a phase 3 brepocitinib trial signals that larger studies are underway, but no results were included in the provided material, so it does not yet change what can be concluded from this month's evidence. [1] [2] [3] [4] [5]

Across studies, researchers looked for practical ways to detect lung involvement earlier and to estimate short-term risk in people with dermatomyositis and related muscle diseases. Overall, combinations of tests tended to perform better than any single test, but prediction was less reliable in rapidly worsening interstitial lung disease. [6] [7]

In a single-center study of 162 people with idiopathic inflammatory myopathy, a blood marker called KL-6 and lung ultrasound B-lines each helped identify interstitial lung disease when compared with high-resolution chest CT scans. Using both together had very high accuracy in this dataset, but in an exploratory subgroup with rapidly progressive interstitial lung disease, prediction was much weaker. [6]

In a small single-center cohort of 17 hospitalized patients with anti-MDA5 antibody-positive interstitial lung disease, people who died in the hospital had higher peak inflammation markers (ferritin, C-reactive protein, and LDH) than those who survived. However, there was substantial overlap between survivors and non-survivors, suggesting these blood tests alone cannot precisely predict outcomes for an individual patient. [7]

A larger biomarker study focusing on anti-MDA5-positive dermatomyositis reported that a neutrophil RNA signal (Lnc-ZCCHC13-18:1) was higher in this group and was linked to risk of rapidly progressive interstitial lung disease in their analyses, alongside factors such as KL-6 and ferritin. This supports ongoing research into blood-based tools for identifying higher-risk patients, but it still needs broader confirmation. [8]

Another retrospective study used quantitative CT analysis in polymyositis/dermatomyositis patients without diagnosed interstitial lung disease and found lower small blood-vessel volume measures in the lungs compared with healthy controls, without differences in lung volume or density. The authors interpreted this as possible subclinical (not yet obvious) lung blood-vessel change, but it is not yet clear how this relates to symptoms or future lung disease. [9]

For patients and caregivers, this group of studies mainly adds background on how clinicians and researchers are trying to measure lung involvement and risk using noninvasive tests (blood tests, ultrasound, and CT-based measurements). These tools may help with screening or monitoring at the group level, but uncertainty remains about how well they predict fast-worsening lung disease or an individual person s outcome, and several results come from single centers or small cohorts that need validation. [6] [7] [8] [9]

Across clinical reports, the focus was on what care can look like when interstitial lung disease becomes very severe, including use of extracorporeal life support (a machine that supports oxygen and/or circulation) and consideration of transplantation in selected situations. A separate cohort described a less common lung scarring pattern seen in some autoimmune rheumatic diseases, including dermatomyositis, that can add long-term breathing burden. [10] [11] [12]

Two adult men with anti-MDA5-positive rapidly progressive interstitial lung disease received sequential double-lung transplantation with extracorporeal membrane oxygenation (ECMO) bridging in a single-center report. Both initially recovered enough to be discharged, one died about 8 months later from a cerebral infarction, and the other remained clinically stable for over a year; both became negative for anti-MDA5 antibodies after transplant. This is early evidence from two patients and cannot predict what will happen for most people. [10]

One case report described a 31-year-old woman with dermatomyositis-associated interstitial lung disease and severe respiratory failure complicated by right heart injury. She was supported with changing ECMO configurations, ultimately a hybrid setup, which stabilized her enough for transfer for heart-lung transplantation. As a single-patient report, it shows what is technically possible but does not establish typical outcomes. [11]

In a Mayo Clinic cohort of 15 people with systemic autoimmune rheumatic disease and pleuroparenchymal fibroelastosis (a specific upper-lung scarring pattern), dermatomyositis accounted for 3 cases. In this group, 40% required supplemental oxygen, 5 had pulmonary hypertension, and 3 died during follow-up; over half also had another interstitial lung disease pattern on imaging. This study describes outcomes in a selected referral population and may not reflect risk in all clinics. [12]

A 2025 Japanese guide for connective tissue disease-associated interstitial lung disease summarized structured approaches to diagnosis, screening, risk factors, acute worsening, rehabilitation, and updated management pathways for polymyositis/dermatomyositis-associated interstitial lung disease. It emphasizes multidisciplinary care and recognizes that different connective tissue diseases can require different management approaches. [13]

One exploratory lab and animal study tested nerandomilast (a PDE4B inhibitor) in a mouse model of myositis-associated interstitial lung disease and in cell experiments, with limited supportive analysis of lung tissue from two dermatomyositis-interstitial lung disease patients. The drug reduced inflammation and scarring signals in mice and affected pathways related to neutrophil traps and blood-vessel lining cell changes; this is preclinical work and does not show clinical benefit in people with dermatomyositis. [14]

For patients, these papers describe the outer edges of care: rare situations where intensive life support and transplantation were used, and a less common lung scarring pattern that may contribute to oxygen needs or pulmonary hypertension in some people. Most evidence here is from case reports or retrospective cohorts, so it mainly helps explain what clinicians may discuss in advanced disease rather than providing clear expectations or proven new treatments; laboratory drug studies are early-stage and not the same as human trials. [10] [11] [12] [13] [14]

These papers looked at how well different tests and biomarkers line up with dermatomyositis (DM) and related lung complications. Overall, results suggested that some tests are clearer when strongly positive (such as anti-MDA5), while borderline results and newer research tools may need confirmation or further validation before they can be relied on widely. Several studies focused on the lungs, aiming to detect changes early or to screen for interstitial lung disease (ILD) in people with inflammatory muscle diseases. [15] [6] [9] [16]

In a two-phase study from Hungary, strong anti-MDA5 antibody immunoblot results usually matched a gold-standard method, but borderline or weak results often did not. In the retrospective part, only 1 of 64 people with borderline immunoblot results had dermatomyositis, and in a small pilot comparison, immunoprecipitation confirmed anti-MDA5 in 3 of 10 samples. This means a borderline anti-MDA5 result may be harder to interpret without the full clinical picture and, in unclear cases, confirmatory testing. [15]

In a single-center observational study of 162 people with idiopathic inflammatory myopathy, a blood marker (KL-6) and lung ultrasound B-lines each helped identify ILD when compared with high-resolution CT as the reference. Using both measures together had very high overall separation between ILD and non-ILD in this dataset (combined AUC 0.984). However, in an exploratory subgroup with rapid-progressive ILD, prediction appeared weaker (AUC around 0.65), suggesting this approach may be less reliable for the fastest-worsening lung cases. [6]

A separate retrospective study used quantitative CT to look for subtle lung blood-vessel related differences in people with polymyositis/dermatomyositis who did not have ILD, compared with healthy controls. The study found lower standardized measures of lung blood-vessel volume across the lungs, and the right middle lobe measure best separated the groups (AUC 0.870), while overall lung volume and density were similar. These results suggest there can be measurable lung vascular differences even without ILD on scans, though what that means for symptoms or outcomes was not answered here. [9]

One exploratory multi-omics analysis combined gene-expression datasets and single-cell data to propose an 18-gene diagnostic risk score for dermatomyositis and highlighted a gene called BTN3A2 as a possible diagnostic marker. The score performed very well in one dataset (AUC 0.957) but less well in an external validation dataset (AUC 0.724), and the signals were most prominent in certain immune cells such as monocytes and some T cells. This suggests gene-based tools may help distinguish DM in research settings, but performance can vary across datasets. [16]

For patients and caregivers, this group of studies mainly adds context about how diagnosis-related testing is evolving and why results sometimes look confusing. The anti-MDA5 paper highlights that borderline blood test results may not match the diagnosis, while strong positives were more consistent, which helps explain why clinicians may interpret results cautiously. The lung-focused studies suggest that combining a blood marker with ultrasound, and using advanced CT measurements, can pick up differences related to lung involvement or lung vessel changes, but questions remain about how these tools perform across hospitals, in diverse patient groups, and especially in rapid-progressive lung disease.

This group of papers shows that dermatomyositis can involve problems beyond weakness and rashes, including calcium deposits under the skin (calcinosis), serious stomach and bowel complications in some children, and long-term cardiovascular death trends at the population level. The overall direction was mixed: some risks were linked to worse outcomes in a specific subgroup, while broader U.S. mortality rates declined over time. Several reports were exploratory or single-patient case reports, so not every detail will apply to most people.

In a retrospective cohort of 57 anti-NXP2 positive juvenile dermatomyositis patients, severe gastrointestinal involvement was linked to substantially higher death risk: 5 of 19 children with gut complications died, compared with 0 of 38 without gut involvement. The gut-complication group more often had signs of severe disease and inflammation, and most had a preceding infection. [17]

Two adult dermatomyositis reports focused on calcinosis and highlighted that it can be extensive and may raise difficult diagnostic questions. One study examined calcinosis in adults and reported a relationship with anti-NXP2 antibodies plus a distinct pattern of where calcium deposits appeared on the body, suggesting calcinosis may not look the same in every antibody subgroup. [18]

A separate case report described one 50-year-old woman with adult-onset dermatomyositis whose diffuse calcinosis initially looked like cancer on imaging, but biopsy showed fat necrosis with dystrophic calcification and no malignancy. Her blood test for anti-TIF1-gamma became positive years after diagnosis, leading to renewed cancer screening; her muscle enzyme level fell over time alongside partial clinical improvement on immunosuppressive therapy. [19]

Beyond dermatomyositis alone, a national U.S. analysis of death certificate data from 1999 to 2020 found cardiovascular death rates in people with systemic connective tissue diseases declined overall, and dermatomyositis showed a steep decline among the subtypes examined. The same analysis also reported differences by sex, race and ethnicity, geography, and rural versus urban settings, meaning improvements were not evenly shared across groups. [20]

One additional case report described a woman in her 70s with amyopathic dermatomyositis (skin disease with preserved strength) who also had persistent high eosinophils in the blood after other causes were excluded. In that single patient, corticosteroid treatment was followed by clearing of skin lesions and normalization of eosinophil counts, showing that unusual blood test patterns can sometimes accompany dermatomyositis without obvious muscle involvement. [21]

For patients and caregivers, these papers reinforce that dermatomyositis is not only a muscle and skin condition: complications can involve the gut, calcium deposits under the skin, and cardiovascular outcomes at a population level. The strongest evidence here comes from the juvenile dermatomyositis cohort (showing worse outcomes when severe gut involvement occurs) and the national mortality analysis (showing improving cardiovascular death trends but ongoing disparities), while the calcinosis and eosinophilia reports add detail mainly as background and may not predict what will happen for any one person. Many uncertainties remain, including why calcinosis appears in certain antibody groups and why severe gut complications cluster in some anti-NXP2 positive children but not others.

Across these studies, cancer stood out as an important factor connected to survival in people with idiopathic inflammatory myopathies, especially dermatomyositis. Evidence from two observational cohorts suggests dermatomyositis had higher death risk than other myositis subtypes, and having cancer further increased risk; a smaller piece of evidence (a single case) illustrates that blood cancer can occur alongside dermatomyositis but does not show what is typical. [22] [23] [24]

In a nationwide Swedish registry cohort of 2,346 adults with idiopathic inflammatory myopathies, 326 people developed cancer after myositis, and 37 later developed a second, separate cancer. Over the full follow-up, the cumulative chance of a second cancer after the first cancer was 22%, while the absolute risk within four years after the first cancer was under 5%. Men and people with a prior cancer history had higher risk of a second cancer. [22]

The same Swedish cohort reported high mortality after a second cancer, with a 3-year all-cause mortality risk of 46%. People with dermatomyositis had a markedly higher death risk after a second cancer than those with other myositis subtypes. This result describes outcomes after a second cancer diagnosis and does not explain why the risk is higher. [22]

In a separate hospital-based retrospective cohort of 225 people with idiopathic inflammatory myopathies (followed 2010 to 2022), dermatomyositis had the highest mortality risk compared with other subtypes, while antisynthetase syndrome had the lowest. Having a malignancy was linked to a much higher mortality risk in this cohort. These findings support that cancer status and myositis subtype can strongly shape overall outcomes, but they come from observational data that cannot prove cause and effect. [23]

A single pediatric case report described a boy with juvenile dermatomyositis who later developed acute myeloid leukemia and had sustained remission of both conditions after leukemia chemotherapy followed by an allogeneic stem cell transplant. This is one patient and may not reflect the usual experience for most people with dermatomyositis, especially adults. [24]

For patients and caregivers, this set of papers mainly adds context about prognosis when cancer occurs in dermatomyositis: in observational cohorts, cancer and dermatomyositis subtype were linked to higher death risk, and a Swedish registry study also quantified second primary cancers after a first cancer. What remains uncertain is how much these risks vary by individual factors (such as specific cancer type, timing, or treatments) because the studies summarized here do not break outcomes down in that level of detail, and the pediatric report is not generalizable.

One exploratory genetics study suggests dermatomyositis and polymyositis share some inherited genetic risk patterns with multiple B-cell lymphomas. The overall message is biological: the overlap mapped to genes and pathways involved in immune signaling and regulation of how cells survive or die, which may help researchers understand why these diseases can be linked in some people. [25]

Using European-ancestry genetic datasets, the researchers identified multiple genetic regions tied to diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma when they conditioned lymphoma results on dermatomyositis or polymyositis results. They then mapped these regions to nearby genes and regulatory signals (for example, signals affecting gene activity in blood or immune cells), highlighting immune-related mechanisms across subtypes. The authors noted key limits, including the need for replication and the fact that some functional annotations came from noncancer tissues. [25]

This genetics work is mainly background research rather than something that changes care today. It suggests that some shared inherited biology may connect dermatomyositis or polymyositis with certain lymphomas at the population level, but it does not provide a clear way to predict lymphoma risk for an individual person, and the findings need confirmation in additional studies.

Across these studies, outcomes in dermatomyositis and related muscle-inflammation conditions were strongly shaped by infections and which organs were involved, especially the lungs and, in some children, the gut. Several reports also pointed to certain autoantibodies (immune system markers in the blood) as signals of higher-risk situations, but the strength of prediction varied. Overall, larger studies supported clear risk patterns (for example, infection risk factors and higher death risk with cancer), while small single-center biomarker work suggested trends but left uncertainty about how well any one lab value can forecast an individual patient's course. [26] [23] [17] [7]

In a systematic review pooling 31 studies (14,548 people with idiopathic inflammatory myopathies), about 24% had an infection, and respiratory tract infections were the most common. Higher infection risk was linked to anti-MDA5 positivity, rapidly progressive interstitial lung disease, dermatomyositis phenotype, older age, low lymphocyte count, and more intensive immune-suppressing treatments; in contrast, anti-TIF1-gamma positivity and TMP-SMX prophylaxis were linked to lower infection risk in the included studies. In plain terms, both immune system features (antibodies and low infection-fighting cells) and the type/intensity of treatment tended to travel with infection risk. [26]

In a hospital-based cohort of 225 people followed over 2010 to 2022, dermatomyositis had the highest death risk compared with other idiopathic inflammatory myopathy subtypes, while antisynthetase syndrome had better survival. Having a malignancy (cancer) was linked to a markedly higher risk of death in this cohort, highlighting that cancer status can be a major driver of outcomes when it occurs alongside these conditions. [23]

In a study of 57 anti-NXP2 positive juvenile dermatomyositis patients, severe gastrointestinal (GI) complications were tied to substantially worse survival: 26.3% (5/19) of the GI group died versus 0% (0/38) in those without GI involvement. The GI-complication group more often had signs of more severe overall illness, including poorer muscle strength, lower body weight measures, lower hemoglobin and albumin, lower lymphocyte counts, and higher inflammation markers; prodromal infections were also common. This suggests that, in this specific juvenile subgroup, severe GI involvement clustered with infection, malnutrition markers, and high inflammation, and it aligned with higher risk. [17]

A small single-center cohort (17 hospitalized patients) focused on anti-MDA5 positive interstitial lung disease and compared survivors to non-survivors. Peak inflammatory markers during hospitalization (especially LDH and CRP, and also ferritin) were higher in those who died, but there was substantial overlap between groups, meaning no single blood marker cleanly separated who would survive from who would not. This study suggests inflammation level relates to risk in this setting, while also underscoring that single lab values may be insufficient for precise prediction without considering the full clinical picture. [7]

In a multicenter Italian cohort of 228 people with idiopathic inflammatory myopathies, male sex, anti-MDA5 positivity, and greater accumulated disease damage were linked to higher disease activity. The study also reported that the MYOACT disease activity score helped identify risk for intensive care unit admission in that cohort. In everyday terms, some baseline traits (sex and antibody status) and overall damage level tracked with more active disease and more severe hospital needs in this group. [27]

For patients and caregivers, this set of papers mainly clarifies which situations tend to come with higher risk: infections (especially affecting breathing), lung involvement linked to anti-MDA5, cancer when present, and severe GI involvement in a specific juvenile dermatomyositis subgroup with anti-NXP2. It also highlights a limit: even when certain inflammation blood markers are higher in people with worse outcomes, a single test may not be enough to predict what will happen for an individual person, particularly in small studies. Some results are broad (a large review of infection risk), while others may apply only to narrower groups (children with anti-NXP2, or hospitalized anti-MDA5 lung disease patients), so uncertainty remains about how well each finding carries over to all people with dermatomyositis. [26] [23] [17] [7] [27]

Across two exploratory studies of public Reddit discussions, daily impact came through strongly: many posts focused on symptoms that interfere with normal routines and quality of life, along with the stress of figuring out what is happening and how to navigate care. Overall tone was usually neutral and information-focused, but shifted more negative when people described ongoing, unresolved problems or uncertainty about diagnosis. [28] [29]

In one large analysis of posts and comments from 2020 to 2024, six main conversation areas repeatedly showed up, including symptoms and organ concerns, fatigue/mobility/sleep, navigating care pathways, day-to-day life impact, and coping and anxiety. More negative sentiment was linked to situations where symptoms were not getting resolved and where people felt unsure about their diagnosis. [28]

A separate analysis that focused specifically on pain found that pain terms appeared in 63.0% of posts, suggesting pain is a common part of what people choose to discuss online. Muscle was the most mentioned body area, and the way people talked about pain clustered with core disease concepts, dermatomyositis skin features, sensory or nerve-like pain descriptions, and other autoimmune conditions. [29]

These studies do not measure symptoms directly in clinics, but they help document what patients and caregivers most often describe as affecting daily life in real-world conversations: pain, fatigue, sleep disruption, mobility limits, and worry during periods of uncertainty. Because the data come from one English-language social media platform and rely on automated text tools, it is not clear how well these patterns represent all people living with dermatomyositis or other myositis types, and they cannot show how symptoms change over time for an individual. [28] [29]